Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$17.83

0.7 (4.09%)

07:09
05/31/19
05/31
07:09
05/31/19
07:09

Iovance Biotherapeutics announces updated data from LN-145 study

Iovance Biotherapeutics announced updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced melanoma. At 7.4-month median follow-up in the ongoing study of LN-145 in advanced cervical cancer, an 11% complete response rate, or CR, was seen. Furthermore, the median duration of response had not been reached. At 8.8-month median follow-up in the ongoing study of lifileucel in advanced melanoma, median duration of response had not been reached. Updated data from the ongoing innovaTIL-04 and innovaTIL-01 studies will be presented at the American Society of Clinical Oncology, or ASCO. As of May 14, data from the innovaTIL-04 study in 27 patients with recurrent, metastatic or persistent cervical cancer demonstrated an objective response rate of 44% and a disease control rate of 85%. At 7.4-month median follow-up, 10 patients maintained a response and the median DOR had not been reached. The mean patient age was 45 years and study participants had experienced a mean of 2.4 prior lines of therapy. As of May 8, results from Cohort 2 in the ongoing innovaTIL-01 study demonstrated an ORR of 38% in 66 consecutively dosed post-PD-1 patients with Stage IIIC/IV unresectable melanoma. In this study, patients had experienced a mean of 3.3 lines of prior therapy including anti-PD1 blocking antibody, and the patients had a high baseline tumor burden. The disease control rate was 80%. At 8.8-month median follow-up, median DOR had not been reached.

  • 31

    May

  • 04

    Jun

  • 10

    Jun

  • 19

    Jun

  • 26

    Jun

IOVA Iovance Biotherapeutics
$17.83

0.7 (4.09%)

05/23/19
WELS
05/23/19
NO CHANGE
Target $32
WELS
Outperform
Iovance Biotherapeutics price target raised to $32 from $23 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics to $32 from $23 following FDA breakthrough therapy designation for its TIL cell therapy LN-145 in cervical cancer. With ongoing pivotal development in melanoma, the analyst sees a second potential accelerated path to market with breakthrough therapy designation in cervical cancer and sees upside potential to further regulatory update on LN145. Birchenough reiterates an Outperform rating on the shares.
05/16/19
BARD
05/16/19
NO CHANGE
Target $34
BARD
Outperform
Iovance Biotherapeutics price target raised to $34 from $29 at Baird
Baird analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $34 from $29 and maintained an Outperform rating, citing increased tumor-infiltrading lymphocyte technology conviction on ASCO abstracts in cervical cancer and metastatic melanoma. The abstracts for Phase 2 data for TIL technology increases his conviction in Iova's TILs, particularly in cervical cancer, the analyst says in a research note.
05/16/19
JEFF
05/16/19
NO CHANGE
Target $29
JEFF
Buy
Jefferies calls Iovance 'big winner' at ASCO, sees up to 40% share rally
Jefferies analyst Biren Amin calls the data reported by Iovance Biotherapeutics (IOVA) the "big winner" for the American Society of Clinical Oncology annual meeting. The ASCO update suggests Iovance's tumor infiltrating lymphocytes therapy could open the door for cell therapy in the "lucrative" solid-tumor market, Amin tells investors in a research note. He points out the company reported that no new patients have progressed in the melanoma trial and offered first evidence of clinically meaningful durability for TIL therapy. Also, its cervical data that reported a 44% overall response rate is three-times greater than reported with Merck's (MRK) Keytruda in a similar patient population, contends Amin. He believes last night's update could drive a 30%-40% rally in shares of Iovance. The analyst keeps a Buy rating on the name with a $29 price target. Iovance in premarket trading is up 26%, or $2.97, to $14.20.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $20
PIPR
Overweight
Iovance Biotherapeutics well positioned in T-cell therapy, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $20 price target on Iovance Biotherapeutics after its Q1 results also disclosed that 3 of its abstracts submitted to ASCO have been accepted. The analyst believes that the company's lifileucel in melanoma update has a "clear opportunity to improve", whiles its LN-145 in cervical cancer data set could be supportive of an accelerated development path. Catanzaro sees Iovance Biotherapeutics as a "best-positioned T-cell therapy" stock, with $440M in cash on hand being sufficient to fund its operations into 2022.

TODAY'S FREE FLY STORIES

AAPL

Apple

$207.21

4.59 (2.27%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:28
07/22/19
07/22
17:28
07/22/19
17:28
Periodicals
Apple may pay $1B or more for Intel patents, staff in chip unit deal, WSJ says »

Apple (AAPL) is in…

AAPL

Apple

$207.21

4.59 (2.27%)

INTC

Intel

$51.36

1.1 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 03

    Aug

ATVI

Activision Blizzard

$45.57

0.43 (0.95%)

17:26
07/22/19
07/22
17:26
07/22/19
17:26
Hot Stocks
Blizzard co-founder Frank Pearce departing after 28 years »

One of the founders of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 05

    Sep

NBSE

NeuBase Therapeutics

$3.55

-0.58 (-14.04%)

17:25
07/22/19
07/22
17:25
07/22/19
17:25
Hot Stocks
Carnegie Mellon reports 5.5% passive stake in NeuBase Therapeutics »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CADE

Cadence Bancorp

$15.86

-3.75 (-19.12%)

17:23
07/22/19
07/22
17:23
07/22/19
17:23
Downgrade
Cadence Bancorp rating change  »

Cadence Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 06

    Aug

  • 26

    Aug

  • 23

    Sep

CAL

Caleres

$18.27

0.27 (1.50%)

17:22
07/22/19
07/22
17:22
07/22/19
17:22
Hot Stocks
Caleres, Veronica Beard announce exclusive footwear partnership »

Caleres and Veronica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AAPL

Apple

$207.21

4.59 (2.27%)

, INTC

Intel

$51.36

1.1 (2.19%)

17:22
07/22/19
07/22
17:22
07/22/19
17:22
Periodicals
Breaking Periodicals news story on Apple, Intel »

Apple in advanced talks…

AAPL

Apple

$207.21

4.59 (2.27%)

INTC

Intel

$51.36

1.1 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 03

    Aug

EFSC

Enterprise Financial

$39.39

-0.58 (-1.45%)

17:19
07/22/19
07/22
17:19
07/22/19
17:19
Earnings
Enterprise Financial reports Q2 EPS 98c, consensus 93c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

TTEC

TTEC Holdings

$47.31

0.04 (0.08%)

17:19
07/22/19
07/22
17:19
07/22/19
17:19
Syndicate
Breaking Syndicate news story on TTEC Holdings »

TTEC Holdings files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

TTEC

TTEC Holdings

$47.31

0.04 (0.08%)

17:18
07/22/19
07/22
17:18
07/22/19
17:18
Syndicate
Breaking Syndicate news story on TTEC Holdings »

TTEC Holdings files $350M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

VBTX

Veritex

$25.67

-0.44 (-1.69%)

17:17
07/22/19
07/22
17:17
07/22/19
17:17
Earnings
Veritex reports Q2 EPS 59c, consensus 62c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 26

    Aug

  • 23

    Sep

WM

Waste Management

$117.15

0.39 (0.33%)

17:12
07/22/19
07/22
17:12
07/22/19
17:12
Initiation
Waste Management initiated  »

Waste Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

IBTX

Independent Bank

$55.08

-1.08 (-1.92%)

17:05
07/22/19
07/22
17:05
07/22/19
17:05
Earnings
Independent Bank reports Q2 adjusted EPS $1.22, consensus $1.27 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 26

    Aug

  • 23

    Sep

RNST

Renasant

$34.10

-0.49 (-1.42%)

17:04
07/22/19
07/22
17:04
07/22/19
17:04
Earnings
Renasant reports Q2 EPS 80c with items, consensus 81c »

Reports Q2 net loan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Sep

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

17:03
07/22/19
07/22
17:03
07/22/19
17:03
Hot Stocks
Steel Dynamics announces planned new flat roll steel mill site selection »

Steel Dynamics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

17:02
07/22/19
07/22
17:02
07/22/19
17:02
Hot Stocks
Brown & Brown reports Q2 organic revenue up 3.9% »

Reports Q2 EBITDA margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

HAE

Haemonetics

$122.44

0.35 (0.29%)

17:02
07/22/19
07/22
17:02
07/22/19
17:02
Hot Stocks
Haemonetics updates financial reporting segments »

Haemonetics Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

  • 05

    Sep

  • 09

    Sep

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

17:01
07/22/19
07/22
17:01
07/22/19
17:01
Earnings
Brown & Brown reports Q2 adjusted EPS 32c, consensus 28c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

DLX

Deluxe

$41.95

0.41 (0.99%)

17:00
07/22/19
07/22
17:00
07/22/19
17:00
Hot Stocks
Deluxe names Chris Thomas chief revenue officer »

Deluxe Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 19

    Sep

GE

General Electric

$10.22

0.18 (1.79%)

, AVCO

Avalon GloboCare

$2.05

-0.105 (-4.88%)

16:57
07/22/19
07/22
16:57
07/22/19
16:57
Hot Stocks
Avalon GloboCare and GE Healthcare announce strategic partnership »

Avalon GloboCare (AVCO)…

GE

General Electric

$10.22

0.18 (1.79%)

AVCO

Avalon GloboCare

$2.05

-0.105 (-4.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 09

    Sep

  • 09

    Sep

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

16:55
07/22/19
07/22
16:55
07/22/19
16:55
Hot Stocks
Breaking Hot Stocks news story on Viveve 

Viveve trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFF

Village Farms

$10.69

0.48 (4.70%)

16:53
07/22/19
07/22
16:53
07/22/19
16:53
Initiation
Village Farms initiated at Craig-Hallum »

Village Farms initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$75.72

0.995 (1.33%)

16:53
07/22/19
07/22
16:53
07/22/19
16:53
Hot Stocks
Best Buy beneficial owner Richard Schulze sells $32.4M in company shares »

Best Buy beneficial owner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

ORGO

Organogenesis

$5.85

-0.27 (-4.41%)

16:50
07/22/19
07/22
16:50
07/22/19
16:50
Syndicate
Organogenesis commences exchange offer »

Organogenesis Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

WD

Walker & Dunlop

$55.46

-0.39 (-0.70%)

16:49
07/22/19
07/22
16:49
07/22/19
16:49
Hot Stocks
Walker & Dunlop appoints Chief Production Officer to Lead FHA finance team »

Walker & Dunlop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 15

    Aug

EQBK

Equity Bancshares

$24.43

-0.19 (-0.77%)

16:49
07/22/19
07/22
16:49
07/22/19
16:49
Earnings
Equity Bancshares reports Q2 EPS 58c, consensus 60c »

The net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.